Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M1\GZ2Z2dmO2aX;uJGF{e2G7 NXSxbm1yOC55zszN M4XpUFI1cA>? MlW3[ZRp[W6xbB?= MUXlcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm NV;LZnc4OjV5OEewO|k>
TE13 MmHwSpVv[3Srb36gRZN{[Xl? MW[wMlPPxE1? Mon4NlRp NIjCfIx2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> MXyyOVU4QTZ4NR?=
TE13 MnjsRZBweHSxc3nzJGF{e2G7 NUHnWIJxOC5|zszN NWLQcpo3OjSq NWLnd2xHcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= MkTXNlU2Pzl4NkW=
MEFs NWrtOZlxTnWwY4Tpc44hSXO|YYm= NUfEXoxuPc7:TR?= NY\IVHZ7OT[q M2jzXYlv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? NYTuOYJwOjV2OEK2N|Q>
SW480  Ml21SpVv[3Srb36gRZN{[Xl? MYWwMlHPxE1? MXi0PIg> M4[3c2ROW09? MontdoV3\XK|ZYOgSW1V MYOyOVQ{PDl7Nx?=
PC3  MWDGeY5kfGmxbjDBd5NigQ>? NXfhdnl7OC5zzszN NI\ufHc1QGh? NYPubmdMTE2VTx?= NEXWcVNz\X[ncoPld{BGVVR? NHGweYQzPTR|NEm5Oy=>
SW480  NF\T[W1HfW6ldHnvckBCe3OjeR?= NHy0SnUxNjIQvF2= NUe3W5I1PDiq MWXEUXNQ NV\EO4p4[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u M3GwPVI2PDN2OUm3
PC3  MYLGeY5kfGmxbjDBd5NigQ>? NH\seJcxNjIQvF2= NVT1ZpMzPDiq MYTEUXNQ MV\heJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? MoD0NlU1OzR7OUe=
SW480  MmrqSpVv[3Srb36gRZN{[Xl? NGG3S5oxNjIQvF2= MVq0PIg> MnGwSG1UVw>? MnrpbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? M1rWbVI2PDN2OUm3
PC3  NVHkWJJYTnWwY4Tpc44hSXO|YYm= NYDVPWFPOC5zzszN Mln6OFhp NGq1S2VFVVOR MV\pcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz NHrQUWgzPTR|NEm5Oy=>
A431 M1PzWGFxd3C2b4Ppd{BCe3OjeR?= NF;DTpgzNzFyL{WwM|ExOG6P M2D1UVQ5cA>? MoXkSG1UVw>? MWPpcohq[mm2czD0bIUh[2WubDDndo94fGh? NIfvOWczPTN5MUC2PS=>
A431 NXvKe481TnWwY4Tpc44hSXO|YYm= NVT0UVh{PTCwTR?= NHXL[HkzNzZxMUKvNlRp MXTEUXNQ NVXxVW05[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u NYPmXZR4OjV|N{GwOlk>
MDA-MB-231 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLNT2IxNTZyMH7N Mn;yNlRp MlvkSG1UVw>? NIHVUpdKSzVyIH;mJFExOG6P MVqyOVE6Ojd{MR?=
MCF7 NXjx[m9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KyUVAuPjBybl2= M{XOXFI1cA>? NH\pXVRFVVOR NFvWbJhKSzVyIH;mJFc2dk1? MWeyOVE6Ojd{MR?=
SKOV-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn74NU0yOM7:TR?= NYeyS3RGOjSq MmSzSG1UVw>? Mn\0TWM2OCCxZjC1MlbPxE1? M3K1N|I2OTZ7NEmx
A549 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyxMVEx|ryP MmDvNlRp M{ThVWROW09? NVzwbGt{UUN3MDDv[kA{NjMQvF2= MVGyOVE3QTR7MR?=
SKOV-3 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv0eJAxNjFvMd88US=> NYXhPZc3PDiq NXvTSmQ3TE2VTx?= NGrvRmJKSzVyIH;mJFAvP87:TR?= MlL0NlUyPjl2OUG=
A549 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn0NE4yNTIQvF2= M{i3cFQ5cA>? M4TT[2ROW09? NVPYOpRYUUN3MDDv[kAxNjJ6zszN NUS4UXBYOjVzNkm0PVE>
SKOV-3 M33qUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnLd2h7OC5yMT2wMlnPxE1? M4HZZlczcA>? NYG1O|NNTE2VTx?= M2\RNGlEPTBib3[gNE4{Os7:TR?= M2TwUlI2OTZ7NEmx
A549 NFjvNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWwMlAyNTBwOd88US=> NGD4WXA4Omh? MYjEUXNQ NYL4cI9VUUN3MDDv[kAxNjB4zszN NV7wUVg2OjVzNkm0PVE>
HeLa M3rON2Z2dmO2aX;uJGF{e2G7 NYnyTFAyOjVybl2= NUT5S3l7OT[q NYnEdZhETE2VTx?= M2HpRolv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= NXewbpdyOjVzMU[2PFg>
CNE2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPJNVAxNTZyMH7N MXGyOE81QC95Mni= NWTtemtQcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NHKwWJgzPDl4OUmwNS=>
PC3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHaNVAxNTFyMEDuUS=> MonPNlRp M1K0WGlEPTBib3[gN|Axdk1? NILEWYIzPDh3NE[1PC=>
LNCaP NI\NSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzlNVAxNTFyMEDuUS=> MWCyOIg> MofGTWM2OCCxZjCzNFBvVQ>? NUHKV5BuOjR6NUS2OVg>
HeLa  M124fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn2UIYzOs7:TR?= M{XhR|Q5cA>? M1rt[YRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= NGjlZ|YzPDh2NkGzOS=>
HMEC-1  NHXt[YNHfW6ldHnvckBCe3OjeR?= M4PHcVMxOG6P MUWyOIg> NF7vcpBqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C M4X2SlI1PzFyNkOx
HeLa MYDGeY5kfGmxbjDBd5NigQ>? MVuxcW0> NYrJSI1yOC53aB?= MmHrZYJwdGm|aHXzJJRp\SC2b4ThcEBJTEGFIHHjeIl3cXS7 NV:1ZXZDOjR5MEe0O|Q>
ACP02 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[1UIwzPTBxM{WwM|UxOG6P M4LBNFI1cA>? MX3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O MkW1NlQ3Pjh3NEe=
ACP03 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPBTIwzPTBxM{WwM|UxOG6P NHTtfI0zPGh? NXizUZE3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MU[yOFY3QDV2Nx?=
U87 GBM MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jl[VExOC9|MECvOVAxKG6P NXrobZQyPzJiaB?= NELyVYQyODBnIHX0bIFvd2x? NIixSHJz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> M1fnVlI1PDZ2OESx
U87 GBM MXLGeY5kfGmxbjDBd5NigQ>? Ml35NVAxNzVyMDDOcS=> MWi0PEBp NVXFZll[OTByJTDleIhidm:u NW\1R|I5UW6mdXPld{BU\W6nc3PlcoNmNUyra3WgRYx1\XKjdHnvcpMhcW5iToXjcIVieiCPb4LwbI9td2e7 MXuyOFQ3PDh2MR?=
RPE NXP6SWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7LbGcxNjJxMD60M|AvQC9zIN88US=> NWX0fJFjOjRxNEivO|IhcA>? Ml7HSG1UVw>? NUDnXFlzcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? MWGyOFQ2PjZyMh?=
HT29  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zxZVE5OCCwTR?= MUO3NkBp MVnJR|UxKG:oIEG4NEBvVQ>? M3LIfVI1OzZ6Mk[1
hMSCs NXTzXlJXTnWwY4Tpc44hSXO|YYm= NX3CVWNqPi5{NTDuUS=> MVmyOEBp M4r0W2ROW09? NHS3cHZ{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz NHy0cVgzPDNzMkO1Oi=>
Huh7  NX3nOopTTnWwY4Tpc44hSXO|YYm= NYTtVGpZOC5zL{CuOU8yNjBizszN M2mwbVI1cA>? MoTld5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w Mmr2NlQzPjl4N{K=
SKOV3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOwMlA2NTJizszN NXezNIhTOTBxMkSvOFghcA>? M{fOcmROW09? MWLt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NETUNJUzPDJ{M{iwNS=>
A2780 M3jGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVriO3VTOC5yNT2yJO69VQ>? NUj6XGpmOTBxMkSvOFghcA>? NFTiNI9FVVOR M160[41m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M2r0[lI1OjJ|OECx
SRA01/04  NYjzSpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6wMlIh|ryP MoDZOFghcA>? NUKwXnluTE2VTx?= MVjzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MYiyOFE2Pzh5OB?=
HLEB3 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jGPFAvOiEQvF2= NGXl[5g1QCCq MWLEUXNQ NHzpSJJ{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NF7Ub|EzPDF3N{i3PC=>
SRA01/04  MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuwMlQwOC56IN88US=> MWm0PEBp M{LRV2ROW09? M3LLPYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MkD2NlQyPTd6N{i=
HLEB3 M3HMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\xUIt1OC52L{CuPEDPxE1? NYrKNWdzPDhiaB?= Mo\LSG1UVw>? NYDC[G14cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3PiUFI1OTV5OEe4
HCT116 NU\5dnN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF36NpUxNjJizszN M2HVUVEzKGh? MU\lcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= M4W2elI1OTJ{MkOx
CA46 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH5ZXg{NzZxMUKvNlQwPDhibl2= NY\KNXd5PDhiaB?= NWL4e|lVcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= MUOyOFA3PDl3MR?=
PMNs MXfGeY5kfGmxbjDBd5NigQ>? NYjSUJpYOzBibl2= MVm0PEBp MVXpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= MmfMNlM6QDh4MUe=
H1299 NXflNY1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfHXINtOcLizszNxsA> M{G4e|I1NzR6L{eyJIg> MUPleIhidm:u NYHrZ2xRcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq NV7GdI97OjN7MU[2NFk>
A549 M{nzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvs[|NrOC5{NT:wMlUwOSEQvF2= M2HLWlI1NzR6L{eyJIg> NEfORmVmfGijbn;s NHjHN2RqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NHTZTpEzOzh4N{m5NS=>
H1299 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS1NI5ZOC5{NT:wMlUwOSEQvF2= NEHwbWgzPC92OD:3NkBp NXHqNHYx\XSqYX7vcC=> Mmj1bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NGGxNpozOzh4N{m5NS=>
A549 MYLBdI9xfG:|aYOgRZN{[Xl? NH7jdoIxNjVxMTFOwG0> NF\I[oc1QCCq Mmjm[ZRp[W6xbB?= NGPRWVdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NW\5[opiOjN6Nke5PVE>
H1299 MkL0RZBweHSxc3nzJGF{e2G7 NWrJXpNiOC53L{Gg{txO M3fzNFQ5KGh? NHu5PW1mfGijbn;s NXTlcmZicW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXSyN|g3Pzl7MR?=
SUM149PT MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\nXYZ5Oi95LkWvNVAh|ryP NES2[WU1QCCq NX72SmpITE2VTx?= MlS0bY5lfWOnczDj[YxtKGSnYYToJIF1KDJizszNJIlve2Wwc3n0bZZmdHl? NIXONZMzOzd7Mk[zPC=>
SUM190PT NGrUSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PIZ|UxNzFyMD:yOVAhdk1? M2XBXFQ5KGh? M3HTT2ROW09? M{L4Z4lv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? NWHa[5d7OjN5OUK2N|g>
HCT1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHUcXVvOC5{L{GuNE82NjBizszN NGjLdo4yOi9{ND:zOk81QCCq NHSxcIVqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M2LzVlI{PzdyMECw
Lovo NFnKNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlIwOS5yL{WuNEDPxE1? MkPrNVIwOjRxM{[vOFghcA>? M37rUolv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MlzuNlM4PzByMEC=
AGS M{DFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\mSYhsOC5yMUWtNUDPxE1? MWi3NkBp MUTpcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= NGf2TWozOzd2NUCyOC=>
Huh7 NWnES4drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX23dnRFOSEQvF2= M1fzW|I1KGh? MUjEUXNQ M1fmZ5Jm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh MkHFNlM3PDN7M{O=
ECC1 NVLicmNjTnWwY4Tpc44hSXO|YYm= NG\HdJY2ODBibl2= NWPsZYc3PSCm M1v1NWROW09? NIXwboFqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NH;lZnMzOzV|MEe2PS=>
HEC1A M1PYRWZ2dmO2aX;uJGF{e2G7 M3fWb|UxOCCwTR?= MnTBOUBl M1fGPGROW09? MlTxbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MmjRNlM2OzB5Nkm=
EN1 MnT2SpVv[3Srb36gRZN{[Xl? MXq1NFAhdk1? Mln1OUBl NEjWWmlFVVOR NYHiO2V1cW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NY\K[|RoOjN3M{C3Olk>
MFE296 MULGeY5kfGmxbjDBd5NigQ>? MWm1NFAhdk1? NIWwO5U2KGR? M4fHcmROW09? MULpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? M4DpblI{PTNyN{[5
HASMCs MoXRSpVv[3Srb36gRZN{[Xl? NGjveHIxNTVyMDDuUS=> NEjtNpk3KGR? MkjN[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> MXqyN|UyQDR4Nx?=
U373 MWPGeY5kfGmxbjDBd5NigQ>? NW\WbWR{OC5{NT:wMlUwOSEQvF2= NYrGdXR2OjRiaB?= NWnNXFFLcW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= MUmyN|Q4PDF5MR?=
ARN8  NX;Ce5hxTnWwY4Tpc44hSXO|YYm= NXLGN|VDOC5yNT2yJO69VQ>? Mlz3NlQhcA>? MXHy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> Mn2wNlM1PzB3NEC=
MCF7 MXzGeY5kfGmxbjDBd5NigQ>? MVuwMlA2NTJizszN MXSyOEBp MWDy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NYfvb5pQOjN2N{C1OFA>
H1299  MXLGeY5kfGmxbjDBd5NigQ>? MYiwMlM{6oDVMdMgxtVO NUfBVol4OjRxNEigbC=> NUfrelJiTE2VTx?= M4XrR4lv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= M33xOFI{PDZzOUe1
H1299 M3i1T2Z2dmO2aX;uJGF{e2G7 NXO2d|E1OC53IN88US=> MUS0PEBp M4fUVGROW09? NHfUPI1qdmirYnn0d{B1cGVibXnndoF1d3K7IIDveIVvfGmjbDDjc41jcW6nIIfpeIghe2muaXLpcolv M2fYbFI{PDZzOUe1
H1299 NWnubZBvTnWwY4Tpc44hSXO|YYm= M{L3RlAvPSEQvF2= M3vhU|Q5KGh? NXv3eJJFTE2VTx?= MUTpcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? NH\BOG4zOzR4MUm3OS=>
MG-63  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPt[2wxNjNizszN MX[xNk06PiCq MoDLSG1UVw>? NX3uc4pZcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MkHJNlM1PTF6MUe=
LM8 NHT1XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHBU|MxNjNizszN NFOyVZIyOi17NjDo Mo[1SG1UVw>? NFvzXXFqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu NX3kbVBEOjN2NUG4NVc>
K562 NFnre4pHfW6ldHnvckBCe3OjeR?= M2fUfVAvPSEQvF2= NYrXc4F5OjRiaB?= M1zBRYV1cGGwb3y= M2Dt[YRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv M1LrOVI{PDNyOUW3
HEL MYHGeY5kfGmxbjDBd5NigQ>? MYmwMlUh|ryP M3zVUlI1KGh? NFXtcJFmfGijbn;s NXTsfZBO\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? M12ydFI{PDNyOUW3
HL60 M33I[mFxd3C2b4Ppd{BCe3OjeR?= MmfLNUDPxE1? MUiyOEBp M4DNT4lv\HWlZYRCpINmdGxiZHXheIg> M3LLdVI{PDByNUG5
KG1 NILtZXVCeG:ydH;zbZMhSXO|YYm= NYnJOnI4OSEQvF2= MVuyOEBp NIXBeHpqdmS3Y3XzxsBk\WyuIHTlZZRp MWOyN|QxODVzOR?=
Kazumi M16zWGFxd3C2b4Ppd{BCe3OjeR?= M4GydVEh|ryP M1jReVI1KGh? NYDQd|BwcW6mdXPld:Kh[2WubDDk[YF1cA>? MlzJNlM1ODB3MUm=
K562 MorIRZBweHSxc3nzJGF{e2G7 NF22bnEyKM7:TR?= MmL0NlQhcA>? NV7XcndrcW6mdXPld:Kh[2WubDDk[YF1cA>? NEf1c2MzOzRyMEWxPS=>
THP1 NXLicXI6SXCxcITvd4l{KEG|c3H5 NVXXUWhFOSEQvF2= NGD6Z|IzPCCq NF7vd|JqdmS3Y3XzxsBk\WyuIHTlZZRp M2ruUlI{PDByNUG5
SH-SY5Y NWTmO5duTnWwY4Tpc44hSXO|YYm= NUTVW4hwOjVyIH7N NWnodIg4OTZiaB?= M{XUZYNp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= MYKyN|MzPjR{Mh?=
HEK293 MVLGeY5kfGmxbjDBd5NigQ>? NW\DOGxlOSEEtV5CpC=> NWjQXpJZOThiaNMg Ml3pbY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? NV\EdnVsOjN{OES4OFg>
HTK NV7POHJWTnWwY4Tpc44hSXO|YYm= Mnv0OFAxKG6P M4fE[lczKGh? NVPNdWg{cW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? MnrPNlMzQDRyMEK=
HTK NEW0TWdHfW6ldHnvckBCe3OjeR?= M1vVdVExOC16MEDuUS=> MUO3NkBp M{jaeIJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w M1zTdFI{Ojh2MECy
Caco-2  NH3HRWNHfW6ldHnvckBCe3OjeR?= MXuxJOK2VcLi MX:yOEBp MX7k[YNz\WG|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25? MlvuNlMyQTVyN{C=
HeLa NY\WXXhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDJc5cyODBibl2= NHXmbm4zPCCq NHzS[5JFVVOR Ml;lTWM2OCCxZjCxNFBvVQ>? NFztUHczOzF4NUe0PC=>
HeLa MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXpWWY1OCCwTR?= NGH6SFk1QCCq NX:xb3pFTE2VTx?= MV\JR|UxKG:oIESwcm0> MnnRNlMyPjV5NEi=
HeLa NVvP[pB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDaNlAhdk1? M4XRZVczKGh? NUXpdGp1TE2VTx?= MoTNTWM2OCCxZjCyNI5O MmXoNlMyPjV5NEi=
HeLa M{mzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDldWc1OTBxM{CvOVAhdk1? M{f1TlczKGh? M3jGTGROW09? MUTpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= MYKyN|E3PTd2OB?=
MDA-MB-231 M3\MbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfzRY8zPS12MECgcm0> NFHReYk1QCCq NEe5V5FKSzVyIH;mJFI3Oy5{bl5CpC=> NUDoSIJ5OjNyNUWxPVg>
MCF-7  MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOyOU01ODBibl2= MVO0PEBp M3\OOWlEPTBib3[gNlIxNjSwTR?= NEjpfZczOzB3NUG5PC=>
ECC-1  NGD4d3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HxSlExOCCwTR?= MXKyOEBp NXvOWoxN\XSqYX7vcC=> M1jodIlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= NVPUcpl5OjNyMki4NFM>
HEC-1A M4OwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXFdlJnOTByIH7N M13NblI1KGh? MYLleIhidm:u NHO2OopqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= M3nmcVI{ODJ6OECz
NHAC-kn NIjtVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3tcY0yOC9zMECvOVAxKG6P MljINVIhcA>? MX3EUXNQ NF7N[GRKSzVyIH;mJFUxOG6P M1nSUFI{ODF5OEex
A549 M{fBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnZemgzPTBibl2= MVy2MVczKGh? MoD5SG1UVw>? NUfJS3JZ[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? MYKyNlk6PDd6MB?=
MG-63 NH\MWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy3TZk4OzByIH7N NEjjT|kyOiCq Mmq2SG1UVw>? NYrXXWVXcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= NHLTRmwzOjd7OUOzPC=>
MG-63 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\tOmNbOzByIH7N NUfLOXVQOjRiaB?= MVjEUXNQ M3z5e4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? NIW1flAzOjd7OUOzPC=>
MG-63 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfZO5E{ODBibl2= M1X2N|Q5KGh? M3fQNmROW09? NV30dHRDcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?= MljFNlI4QTl|M{i=
HL60  MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHmNHgyPTBvM{WwJI5O NV30eVJMOjRiaB?= Moi3bY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> NXfTPWt2OjJ5NUO3N|k>
U937 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hx[|E2OC1|NUCgcm0> Mk\qNlQhcA>? MkDmbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> MU[yNlc2Ozd|OR?=
SCC-6 M{CyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz0dIYyOjByLUOyNFAhdk1? M{fLR|EzNzJ2L{S4JIg> MV\EUXNQ NHu0emtqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MXOyNlU2OjN{MR?=
U87  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u5e|ExOC1|MECgcoc> MUiyOEBp MlHxbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd? MlnNNlIzPzB6NEm=
K562 MljUSpVv[3Srb36gRZN{[Xl? NVLMeFZ1OSEQvF2= NH7GRWoyOiCq NXTNeGQ6TE2VTx?= MnXx[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= M2rVVVIzOTd7MUm4
Reh MmjKSpVv[3Srb36gRZN{[Xl? NFnOe5AxNjNxMTFOwG0> MVuxNkBp MnTnSG1UVw>? MlnN[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MYOyNlE4QTF7OB?=

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID